By Samuel Indyk
Investing.com – Synairgen (LON:SYNG) shares were trading higher on Thursday morning after the company announced it has recruited its full 610 randomised patients for its global Phase 3 SPRINTER trial, evaluating SNG001 for the treatment of hospitalised COVID-19 patients.
The Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries.
Once the final patients have completed their initial 35-day trial period, quality assurance and statistical analysis will be completed. Accordingly, top-line data from the trial is expected in early 2022 and, conditional upon a successful trial, the company is preparing to file for Emergency Use Authorisation with the US Food and Drug Administration (FDA) for patients requiring hospitalisation due to COVID-19.
“Even with extensive vaccine programmes, in the US alone, thousands of patients a day are still being hospitalised due to serious COVID-19 symptoms,” said Synairgen CEO Richard Marsden. “We believe that SNG001, our investigational inhaled formulation of interferon beta, a naturally-occurring, broad-spectrum antiviral protein, could offer a compelling new treatment option.”
Synairgen will continue to work on the SPRINTER study with Parexel Biotech, a division of Parexel. Day 35 data will be reported in the first instance followed by the long COVID results which will be collected until Day 90.
At 09:22GMT, shares in Synairgen were trading higher by 5.5% at 191.5 pence per share.